Figure 3, Kaplan-Meier Plot of Composite Outcome of CV Death, HF Hospitalization, or Urgent HF Visit - Clinical Review Report: Dapagliflozin (Forxiga)

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: Dapagliflozin (Forxiga): (AstraZeneca Canada Inc.): Indication: Heart failure with reduced ejection fraction [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Mar.

Cover of Clinical Review Report: Dapagliflozin (Forxiga)

Clinical Review Report: Dapagliflozin (Forxiga): (AstraZeneca Canada Inc.): Indication: Heart failure with reduced ejection fraction [Internet].

Show details

Contents

Figure 3Kaplan-Meier Plot of Composite Outcome of CV Death, HF Hospitalization, or Urgent HF Visit

CI = confidence interval; CV = cardiovascular; D or dapa = dapagliflozin; HF = heart failure; HR = hazard ratio; P = placebo.

Source: Clinical Study Report for DAPA-HF.⁷

From: Clinical Evidence

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Contents

Views

Cite this Page
Clinical Review Report: Dapagliflozin (Forxiga): (AstraZeneca Canada Inc.): Indication: Heart failure with reduced ejection fraction [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Mar. Figure 3, Kaplan-Meier Plot of Composite Outcome of CV Death, HF Hospitalization, or Urgent HF Visit.
PDF version of this title (1.7M)

Other titles in this collection

CADTH Common Drug Reviews

Recent Activity

Clear Turn Off Turn On

Figure 3, Kaplan-Meier Plot of Composite Outcome of CV Death, HF Hospitalization...
Figure 3, Kaplan-Meier Plot of Composite Outcome of CV Death, HF Hospitalization, or Urgent HF Visit - Clinical Review Report: Dapagliflozin (Forxiga)
polygalacturonase E precursor pgaE-Aspergillus niger [Aspergillus niger]
polygalacturonase E precursor pgaE-Aspergillus niger [Aspergillus niger]
gi|134055985|emb|CAK44164.1|
Protein
LOC103993330 [Musa acuminata AAA Group]
LOC103993330 [Musa acuminata AAA Group]
Gene ID:103993330
Gene
LOC100272705 [Zea mays]
LOC100272705 [Zea mays]
Gene ID:100272705
Gene
LOC547542 [Glycine max]
LOC547542 [Glycine max]
Gene ID:547542
Gene

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on